MENU

2025 Satellite Meeting
Drug Discovery for Ion Channels XXV

Friday, February 14, 8:00 AM - 5:15 PM
Room 107AB, Los Angeles Convention Center

PRE-REGISTRATION DEADLINE: January 10, 2025

Register Now

Ion channels are an important class of therapeutic drug targets, and mutations in ion channel genes are found to be responsible for an increasing number of diseases.  While conventional electrophysiological techniques permit the most detailed and direct study of ion channel function, they are limited due to the manual nature of the method and their low throughput.  Because of this, ion channels remain an underrepresented target class for drug discovery. 

The advent of higher throughput automated electrophysiology systems changed the face of ion channel drug discovery.  Since the inaugural “Drug Discovery for Ion Channels” satellite meeting, there have been many advances in ion channel drug discovery including new instrumentation and techniques.  For this year, we propose to continue the “Satellite Meeting” tradition at the Biophysical Society Annual Meeting and review the advances ion channel drug discovery. 

This year’s meeting will highlight presentations from drug discovery companies, companies that provide ion channel services to drug discovery companies and companies that provide products to ion channel drug discovery companies, as well as other speakers in the field of ion channel drug discovery, including several academic speakers. 

 

8:00 AM

Registration and Coffee
8:30 AM Chris Mathes, Metrion Biosciences, USA
Welcome and Opening Remarks
Session I Daniel Sauter, Sophion Bioscience, USA
8:45 AM - 9:30 AM David Adams, University of Wollongong, Australia
GABA B Receptor Modulation of Membrane Excitability in Human Pluripotent Stem Cell-Derived Sensory Neurons by Baclofen and α-conotoxin Vc1.1 
9:30 AM - 10:00 AM John Gilchrist, Latigo Bioterapeutics, USA
Diminazene Reveals Unexpected ASIC Biology
10:00 AM - 10:30 AM Jun Chen, Genentech, USA
Subtype-selective Modulation and Rescue of HCN1 Channel Mutants

10:30 AM - 11:00 AM

Coffee Break
Session II Jean Francois Rolland, Axxam, Italy
11:00 AM - 11:30 AM Stephan Pless, University of Copenhagen, Denmark
Targeting Ion Channels with De Novo Designed Mini Proteins
11:30 AM - 12:00 PM Fernanda Laezza, University of Texas, USA
Mining the Voltage-Gated Na+ Channel for Neurotherapeutics Development
12:00 PM - 12:30 PM Jeremiah Osteen, Vertex Pharmaceuticals, USA
Title to be Announced
12:30 PM - 1:30 PM Lunch
Session III

Chris Mathes, Metrion Biosciences, USA, Chair

1:30 PM - 2:00 PM

Jose Matta, Rapport Therapeutics, USA
Targeting AMPA Receptors in Complex with TARP-g8 for Epilepsy and Pain

2:00 PM - 2:30 PM Xi Huang, Toronto Hospital for Sick Children, Canada
Targeting Potassium Channels in Brain Tumor-Initiating Cells
2:30 PM – 3:00 PM Victoria Assimon, Maze Therapeutics, USA
A Small Molecule Inhibitor of APOL1 Attenuates Albuminuria in a Mouse Model of APOL1 Kidney Disease
3:00 PM - 3:30 PM Coffee Break
Session IV Alison Obergrussberger, Nanion, Germany, Chair
3:30 PM - 400 PM Kris Kahlig, Praxis Precision Medicines, USA
Dynamic Action Potential Clamp for the Functional Classification of SCN2A Variants
4:00 PM - 4:30 PM Jose Mercado, DSM Firmenich, USA
Scrambling Mosquito Olfaction to Deter the Buzzing Menace
4:30 PM - 5:00 PM Nina Ottossen, Linkoping University, Sweden
Title to be Announced
5:00 PM - 5:15 PM Alison Obergrussberger, Nanion, Germany
Closing Remarks
Sponsored by: